Cargando…
Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide
Temozolomide (TMZ) is the main chemotherapeutic drug utilized for the treatment of glioblastoma multiforme (GMB), however, drug resistance often leads to tumor recurrence and poor outcomes. GMB cell lines were treated with TMZ for up to two weeks and then subjected to proteomics analysis to identify...
Autores principales: | Wang, Hai, Feng, Wenfeng, Lu, Yuntao, Li, Hezhen, Xiang, Wei, Chen, Ziyang, He, Minyi, Zhao, Liang, Sun, Xuegang, Lei, Bingxi, Qi, Songtao, Liu, Yawei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931463/ https://www.ncbi.nlm.nih.gov/pubmed/27375225 http://dx.doi.org/10.1038/srep28948 |
Ejemplares similares
-
Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2
por: Yi, Guo-zhong, et al.
Publicado: (2019) -
The DHC1b (DHC2) Isoform of Cytoplasmic Dynein Is Required for Flagellar Assembly
por: Pazour, Gregory J., et al.
Publicado: (1999) -
Cytoplasmic dynein heavy chain: the servant of many masters
por: Schiavo, Giampietro, et al.
Publicado: (2013) -
Conditional Deletion of Cytoplasmic Dynein Heavy Chain in Postnatal Photoreceptors
por: Dahl, Tiffanie M., et al.
Publicado: (2021) -
WDR92 is required for axonemal dynein heavy chain stability in cytoplasm
por: Patel-King, Ramila S., et al.
Publicado: (2019)